Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| MASK | 3 E Network Technology Group | $3.00 | $1.76 | 142.06% | 84.6M | $28M | $1.19$100.00 |
| APLS | Apellis Pharmaceuticals | $40.30 | $23.21 | 135.78% | 2.4M | $2.2B | $16.10$40.45 |
| KIDZ | Classover | $3.46 | $1.41 | 68.78% | 74.7M | $2.5M | $2.01$532.50 |
| CNTA | Centessa Pharmaceuticals Plc | $40.00 | $12.42 | 45.02% | 24.3M | $3.7B | $9.60$40.26 |
| CRMU | Themes ETF Trust - Leverage Shares 2x Long Crml Daily ETF | $5.12 | $1.13 | 28.18% | 39.4K | - | $3.99$15.25 |
| PASG | Passage Bio | $7.84 | $1.66 | 26.78% | 29.8K | $20M | $5.12$20.00 |
| NPT | Texxon | $5.80 | $1.03 | 21.59% | 4.4M | $106M | $3.14$22.38 |
| AGIO | Agios Pharmaceuticals | $35.84 | $6.23 | 21.04% | 85.2K | $1.7B | $22.24$46.00 |
| DWSN | Dawson Geophysical | $3.18 | $0.54 | 20.64% | 335.5K | $82M | $1.08$5.54 |
| WSHP | WeShop | $6.15 | $1.05 | 20.59% | 2.7K | $120M | $5.08$250.00 |
| MODD | Modular Medical | $5.42 | $0.87 | 19.17% | 202.2K | $636M | $3.55$34.50 |
| ALKS | Alkermes Plc | $35.85 | $5.70 | 18.91% | 246.2K | $5.0B | $25.17$36.32 |
| BAER | Bridger Aerospace Group | $2.04 | $0.32 | 18.61% | 5.5K | $96M | $1.02$3.44 |
| KSCP | Knightscope | $4.01 | $0.62 | 18.11% | 7.9K | $45M | $2.45$10.14 |
| UUUG | Themes ETF Trust - Leverage Shares 2x Long Uuuu Daily ETF | $9.82 | $1.45 | 17.32% | 157.8K | - | $8.18$30.00 |
| UGRO | Urban-gro | $24.05 | $3.43 | 16.63% | 2.6M | $15M | $2.02$37.00 |
| MVLL | Graniteshares ETF Trust - GraniteShares 2x Long Mrvl Daily ETF | $24.00 | $3.37 | 16.34% | 648.4K | - | $9.66$32.36 |
| MRVU | Direxion Shares Etf Trust - Daily Mrvl Bull 2x Etf | $31.16 | $4.37 | 16.32% | 35.2K | - | $20.80$35.23 |
| RMCO | Royalty Management | $2.82 | $0.39 | 16.18% | 33.6K | $37M | $0.91$5.00 |
| TRUG | TruGolf | $5.25 | $0.71 | 15.53% | 127K | $2.2M | $3.50$210.00 |
| NCEL | NewcelX | $2.16 | $0.28 | 14.89% | 15.9K | $8.6M | $1.83$30.80 |
| CVKD | Cadrenal Therapeutics | $4.88 | $0.63 | 14.82% | 695 | $9.9M | $4.21$19.03 |
| GLBS | Globus Maritime | $2.20 | $0.25 | 12.82% | 343.6K | $42M | $0.99$2.25 |
Related Articles
Featured Article
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
Cory Renauer|Oct 29, 2024
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.
2 Best Growth Stocks to Buy in April
George Budwell, PhD|Apr 3, 2023
Takeover interest is spurring these two biotech stocks higher.
Wall Street Upgraded This Stock's Price Target After a New Approval: Is It a Buy?
James Halley|Feb 27, 2023
The company's lead therapy was just approved for another indication.
Want to Make Money in Biotech? Do This First
Brian Orelli, PhD and Keith Speights|May 7, 2021
Keeping track of upcoming events is important.
Why Alkermes' Q4 Results Were Better Than They Might Seem
Keith Speights|Feb 11, 2021
The biotech posted a big year-over-year sales decline. But there was a good reason for it.
4 Reasons Agios' Oncology Deal Should Please Investors
Cory Renauer|Dec 22, 2020
Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.
2 Mid-Cap Healthcare Stocks to Buy Now
Cory Renauer|Sep 5, 2020
These drugmakers are in the sweet spot to provide market-beating returns.
The Coronavirus Pandemic Will Delay 2020 IPOs
Joe Tenebruso|Mar 15, 2020
COVID-19 and initial public offerings don’t go well together.
Gene Therapy Biotech Passage Bio IPOs
Brian Orelli, PhD|Feb 28, 2020
The clinical-stage biotech raised $216 million.
Is Apellis Pharmaceuticals a Buy?
Maxx Chatsko|Feb 3, 2020
The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.
